Anivac VHD Suspension for injection for rabbits

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Aktīvā sastāvdaļa:

Rabbit haemorrhagic disease, strain RHDV PHB 98

Pieejams no:

Pharmagal Bio s.r.o

ATĶ kods:

QI08AA01

SNN (starptautisko nepatentēto nosaukumu):

Rabbit haemorrhagic disease, strain RHDV PHB 98

Deva:

minimum 1 PD90

Zāļu forma:

Suspension for injection

Receptes veids:

POM: Prescription Only Medicine as defined in relevant national legislation

Ārstniecības grupa:

Rabbits

Ārstniecības joma:

rabbit haemorrhagic disease virus

Ārstēšanas norādes:

Immunological - Inactivated Vaccine

Autorizācija statuss:

Authorised

Autorizācija datums:

2008-11-10

Produkta apraksts

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Anivac VHD Suspension for injection for rabbits
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose of vaccine (0.5 ml) contains:
_Active substances:_
Inactivated Rabbit Haemorrhagic Disease Virus strain RHDV PHB98
…… min. 1 PD
90
*
_Adjuvant:_
Aluminium hydroxide gel
.................................................................................
1.3 mg
_Excipients:_
Formaldehyde
………………………………………………………………
0.55 mg
Thiomersal
………………………………………………………………
0.05 mg
For a full list of excipients, see section 6.1.
* Protective dose for minimum 90 % of vaccinated animals
3 PHARMACEUTICAL FORM
Suspension for injection.
Suspension of red-brown colour with easily shakeable sediment of
inactivated RHDV adsorbed on aluminium
hydroxide gel that forms 40-60 % of the vaccine if left undisturbed.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Rabbit.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of rabbits to prevent mortality caused by RHD
virus
Onset of immunity: 7 days
Duration of immunity: 1 year based on field data without controlled
challenge
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
No information is available on the use of the vaccine in seropositive
animals including those with maternally derived
antibodies; therefore in situations where high antibody levels are
expected the vaccination protocol should be planned
accordingly.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___